Pregabalin Capsule
Product Images NDC 70518-4569

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4569). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

The image shows a prescription label for Pregabalin Capsules, 225 mg oral capsules, with a quantity of 90 capsules. The label indicates it is repackaged by RemedyRepack Inc., with warnings about federal law restrictions and storage instructions. The capsule color is noted as orange and white. Manufacturer details state Rising Pharma, Inc., Allendale, NJ.*

FDA Label Image

Pregabalin-chem-structure.jpg (Pregabalin Chem Structure)

Chemical structure of pregabalin, showing its molecular framework including an amino group (NH2) and a carboxyl group (CO2H) attached to a carbon backbone with specific stereochemistry indicated.*

FDA Label Image

Pregabalin-equation.jpg (Pregabalin Equation)

A mathematical formula calculating creatinine clearance (CLCr) based on patient age, weight, serum creatinine, and gender adjustment. The formula includes the factors age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier of 0.85 for female patients.*

FDA Label Image

Pregabalin-fig-01.jpg (Pregabalin Fig 01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, illustrating the effectiveness of different doses of Pregabalin in pain improvement.*

FDA Label Image

Pregabalin-fig-02.jpg (Pregabalin Fig 02)

A line chart comparing percent improvement in pain from baseline (x-axis) with percent of patients improved (y-axis) between Pregabalin 100 mg three times a day and placebo. The chart shows higher patient improvement percentages with Pregabalin across pain improvement thresholds.*

FDA Label Image

Pregabalin-fig-03.jpg (Pregabalin Fig 03)

A line graph showing percent of patients improved relative to percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis represents percent of patients improved (0 to 100%).*

FDA Label Image

Pregabalin-fig-04.jpg (Pregabalin Fig 04)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing trends of patient improvement across different pain improvement percentages.*

FDA Label Image

Pregabalin-fig-05.jpg (Pregabalin Fig 05)

A line graph showing the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph indicates the effectiveness of different dosages of Pregabalin compared to placebo in pain improvement.*

FDA Label Image

Pregabalin-fig-06.jpg (Pregabalin Fig 06)

Bar graph depicting responder rates (%) by dose for two studies, E1 and E3. Study E1 compares placebo and four pregabalin doses (150, 300, 450, 600 mg/day), showing increasing responder rates with dose. Study E3 compares placebo and two pregabalin doses (600, 900 mg/day) with higher responder rates at higher doses. The graph includes sample sizes (N) below each group and indicates statistical significance versus placebo.*

FDA Label Image

Pregabalin-fig-07.jpg (Pregabalin Fig 07)

A line graph depicting seizure reduction (median percentage change from baseline) on the y-axis versus dose in mg/day on the x-axis. Four studies are plotted, distinguished by different symbols: Study E1 BD, Study E2 TID, Study E3 BD, and Study E3 TID, showing trends of seizure reduction across increasing doses with significant p-values noted for each data point.*

FDA Label Image

Pregabalin-fig-08.jpg (Pregabalin Fig 08)

A bar chart depicting responder rates (%) for three groups: Placebo (22.6%, n=93), Pregabalin 2.5 mg/kg/day (29.1%, n=103), and Pregabalin 10 mg/kg/day (40.6%, n=96). The y-axis shows responder rate percentages, and the x-axis labels each group with subject counts.*

FDA Label Image

Pregabalin-fig-09.jpg (Pregabalin Fig 09)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo, with the y-axis representing percent of patients improved and the x-axis representing percent improvement in pain.*

FDA Label Image

Pregabalin-fig-10.jpg (Pregabalin Fig 10)

A line chart comparing estimated percent of subjects without LTR (y-axis) over time in days (x-axis) for Pregabalin versus placebo. The chart shows two curves: a solid line for Pregabalin and a dashed line for placebo, illustrating differences in subject outcomes over 180 days.*

FDA Label Image

Pregabalin-fig-11.jpg (Pregabalin Fig 11)

Line graph showing the percent of subjects improved from baseline to Week 12 BOCF, comparing Pregabalin and placebo. The x-axis represents percent improvement ranging from 0 to 100, while the y-axis represents the percent of subjects improved. Solid line corresponds to Pregabalin, and dashed line corresponds to placebo, indicating higher improvement rates for Pregabalin across the spectrum.*

FDA Label Image

Pregabalin-fig-12.jpg (Pregabalin Fig 12)

A line chart comparing the percent of subjects improved from baseline to Week 16 between Pregabalin and placebo groups. The x-axis shows percent improvement ranging from >0 to 100, and the y-axis shows the percent of subjects improved, from 0 to 100 percent. The solid line represents Pregabalin, and the dotted line represents placebo, illustrating higher improvement percentages for Pregabalin across the range.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.